NCT00578565

Rituximab in Rheumatoid Arthritis Lung Disease

Rituximab for the Treatment of Rheumatoid Arthritis-Associated Interstitial Pneumonia: A Pilot Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Eric Matteson · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physical exams and laboratory parameters. * Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological subtype) will be enrolled * The study involves 12 visits over 48 weeks * Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at six months.

Conditions

• Rheumatoid Arthritis
• Interstitial Pneumonia

Interventions

Type	Name	Description
DRUG	Rituximab	Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.

Timeline

• Start date: 2007-05-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2007-12-21
• Last updated: 2012-10-01
• Results posted: 2012-09-25

Locations

2 sites across 1 country: United States